Industry Growth Insights published a new data on “Lung Cancer Diagnostic Tests Market”. The research report is titled “Lung Cancer Diagnostic Tests Market research by Types (Immunoassays, Flow Cytometry, Rapid Tests, Molecular Assays, Tissue Arrays, Circulating Tumor Cells, Pharmacodiagnostics, Biomarkers, Other Diagnostics Methods), By Applications (Precision Medicine, Personalized Medicine, Cancer Monitoring), By Players/Companies Advpharma Inc, AIT Austrian Institute of Technology GmbH, Courtagen Life Sciences Inc, DiagnoCure Inc. (Inactive), BioMark Diagnostics Inc., BioMarker Strategies LLC, Emory University, Epigenomics AG, GlycoZym, HalioDx SAS, Louisville Bioscience, Inc., Mayo Clinic US”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Lung Cancer Diagnostic Tests Market Research Report
By Type
Immunoassays, Flow Cytometry, Rapid Tests, Molecular Assays, Tissue Arrays, Circulating Tumor Cells, Pharmacodiagnostics, Biomarkers, Other Diagnostics Methods
By Application
Precision Medicine, Personalized Medicine, Cancer Monitoring
By Companies
Advpharma Inc, AIT Austrian Institute of Technology GmbH, Courtagen Life Sciences Inc, DiagnoCure Inc. (Inactive), BioMark Diagnostics Inc., BioMarker Strategies LLC, Emory University, Epigenomics AG, GlycoZym, HalioDx SAS, Louisville Bioscience, Inc., Mayo Clinic US
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Lung Cancer Diagnostic Tests Market Report Segments:
The global Lung Cancer Diagnostic Tests market is segmented on the basis of:
Types
Immunoassays, Flow Cytometry, Rapid Tests, Molecular Assays, Tissue Arrays, Circulating Tumor Cells, Pharmacodiagnostics, Biomarkers, Other Diagnostics Methods
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Precision Medicine, Personalized Medicine, Cancer Monitoring
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Advpharma Inc
- AIT Austrian Institute of Technology GmbH
- Courtagen Life Sciences Inc
- DiagnoCure Inc. (Inactive)
- BioMark Diagnostics Inc.
- BioMarker Strategies LLC
- Emory University
- Epigenomics AG
- GlycoZym
- HalioDx SAS
- Louisville Bioscience, Inc.
- Mayo Clinic US
Highlights of The Lung Cancer Diagnostic Tests Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Immunoassays
- Flow Cytometry
- Rapid Tests
- Molecular Assays
- Tissue Arrays
- Circulating Tumor Cells
- Pharmacodiagnostics
- Biomarkers
- Other Diagnostics Methods
- By Application:
- Precision Medicine
- Personalized Medicine
- Cancer Monitoring
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lung Cancer Diagnostic Tests Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Lung cancer diagnostic tests include a physical examination, chest X-ray, CT scan or MRI scan of the lungs.
Some of the major companies in the lung cancer diagnostic tests market are Advpharma Inc, AIT Austrian Institute of Technology GmbH, Courtagen Life Sciences Inc, DiagnoCure Inc. (Inactive), BioMark Diagnostics Inc., BioMarker Strategies LLC, Emory University, Epigenomics AG, GlycoZym, HalioDx SAS, Louisville Bioscience, Inc., Mayo Clinic US.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Lung Cancer Diagnostic Tests Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Lung Cancer Diagnostic Tests Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Lung Cancer Diagnostic Tests Market - Supply Chain
4.5. Global Lung Cancer Diagnostic Tests Market Forecast
4.5.1. Lung Cancer Diagnostic Tests Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Lung Cancer Diagnostic Tests Market Size (000 Units) and Y-o-Y Growth
4.5.3. Lung Cancer Diagnostic Tests Market Absolute $ Opportunity
5. Global Lung Cancer Diagnostic Tests Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Lung Cancer Diagnostic Tests Market Size and Volume Forecast by Type
5.3.1. Immunoassays
5.3.2. Flow Cytometry
5.3.3. Rapid Tests
5.3.4. Molecular Assays
5.3.5. Tissue Arrays
5.3.6. Circulating Tumor Cells
5.3.7. Pharmacodiagnostics
5.3.8. Biomarkers
5.3.9. Other Diagnostics Methods
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Lung Cancer Diagnostic Tests Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Lung Cancer Diagnostic Tests Market Size and Volume Forecast by Application
6.3.1. Precision Medicine
6.3.2. Personalized Medicine
6.3.3. Cancer Monitoring
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Lung Cancer Diagnostic Tests Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Lung Cancer Diagnostic Tests Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Lung Cancer Diagnostic Tests Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Lung Cancer Diagnostic Tests Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Lung Cancer Diagnostic Tests Demand Share Forecast, 2019-2026
9. North America Lung Cancer Diagnostic Tests Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Lung Cancer Diagnostic Tests Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Lung Cancer Diagnostic Tests Market Size and Volume Forecast by Application
9.4.1. Precision Medicine
9.4.2. Personalized Medicine
9.4.3. Cancer Monitoring
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Lung Cancer Diagnostic Tests Market Size and Volume Forecast by Type
9.7.1. Immunoassays
9.7.2. Flow Cytometry
9.7.3. Rapid Tests
9.7.4. Molecular Assays
9.7.5. Tissue Arrays
9.7.6. Circulating Tumor Cells
9.7.7. Pharmacodiagnostics
9.7.8. Biomarkers
9.7.9. Other Diagnostics Methods
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Lung Cancer Diagnostic Tests Demand Share Forecast, 2019-2026
10. Latin America Lung Cancer Diagnostic Tests Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Lung Cancer Diagnostic Tests Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Lung Cancer Diagnostic Tests Market Size and Volume Forecast by Application
10.4.1. Precision Medicine
10.4.2. Personalized Medicine
10.4.3. Cancer Monitoring
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Lung Cancer Diagnostic Tests Market Size and Volume Forecast by Type
10.7.1. Immunoassays
10.7.2. Flow Cytometry
10.7.3. Rapid Tests
10.7.4. Molecular Assays
10.7.5. Tissue Arrays
10.7.6. Circulating Tumor Cells
10.7.7. Pharmacodiagnostics
10.7.8. Biomarkers
10.7.9. Other Diagnostics Methods
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Lung Cancer Diagnostic Tests Demand Share Forecast, 2019-2026
11. Europe Lung Cancer Diagnostic Tests Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Lung Cancer Diagnostic Tests Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Lung Cancer Diagnostic Tests Market Size and Volume Forecast by Application
11.4.1. Precision Medicine
11.4.2. Personalized Medicine
11.4.3. Cancer Monitoring
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Lung Cancer Diagnostic Tests Market Size and Volume Forecast by Type
11.7.1. Immunoassays
11.7.2. Flow Cytometry
11.7.3. Rapid Tests
11.7.4. Molecular Assays
11.7.5. Tissue Arays
11.7.6. Circulating Tumor Cells
11.7.7. Pharmacodiagnostics
11.7.8. Biomarkers
11.7.9. Other Diagnostics Methods
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Lung Cancer Diagnostic Tests Demand Share, 2019-2026
12. Asia Pacific Lung Cancer Diagnostic Tests Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Lung Cancer Diagnostic Tests Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Lung Cancer Diagnostic Tests Market Size and Volume Forecast by Application
12.4.1. Precision Medicine
12.4.2. Personalized Medicine
12.4.3. Cancer Monitoring
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Lung Cancer Diagnostic Tests Market Size and Volume Forecast by Type
12.7.1. Immunoassays
12.7.2. Flow Cytometry
12.7.3. Rapid Tests
12.7.4. Molecular Assays
12.7.5. Tissue Arrays
12.7.6. Circulating Tumor Cells
12.7.7. Pharmacodiagnostics
12.7.8. Biomarkers
12.7.9. Other Diagnostics Methods
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Lung Cancer Diagnostic Tests Demand Share, 2019-2026
13. Middle East & Africa Lung Cancer Diagnostic Tests Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Lung Cancer Diagnostic Tests Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Lung Cancer Diagnostic Tests Market Size and Volume Forecast by Application
13.4.1. Precision Medicine
13.4.2. Personalized Medicine
13.4.3. Cancer Monitoring
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Lung Cancer Diagnostic Tests Market Size and Volume Forecast by Type
13.7.1. Immunoassays
13.7.2. Flow Cytometry
13.7.3. Rapid Tests
13.7.4. Molecular Assays
13.7.5. Tissue Arrays
13.7.6. Circulating Tumor Cells
13.7.7. Pharmacodiagnostics
13.7.8. Biomarkers
13.7.9. Other Diagnostics Methods
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Lung Cancer Diagnostic Tests Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Lung Cancer Diagnostic Tests Market: Market Share Analysis
14.2. Lung Cancer Diagnostic Tests Distributors and Customers
14.3. Lung Cancer Diagnostic Tests Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Advpharma Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AIT Austrian Institute of Technology GmbH
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Courtagen Life Sciences Inc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. DiagnoCure Inc. (Inactive)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. BioMark Diagnostics Inc.
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. BioMarker Strategies LLC
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Emory University
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Epigenomics AG
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. GlycoZym
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. HalioDx SAS
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Louisville Bioscience, Inc.
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Mayo Clinic US
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.
